The ReCell suspension contains basal keratinocytes, melanocytes, fibroblasts and Langerhans cells.

The metabolically responsive epithelial cells migrate across the wound surface, leading to regeneration of skin of normal color and texture.

Avita Medical claims ReCell Spray-On-Skin allows in-theater preparation of a spray-on suspension consisting of cells derived from a small (2x 2cm), thin (0.15-0.20mm) biopsy of a patient’s own skin that is sufficient to cover an area up to 80 times the size of the biopsy.

Avita Medical CEO William Dolphin said ReCell provides significant advantages for the patient and clinician over the use of laser alone, including improved aesthetic outcomes and recovery times.

ReCell is patented, CE-marked for Europe, TGA-registered in Australia and SFDA-cleared in China.

ReCell is an investigational device limited by federal law to investigational use and is not available for sale in the US.